
Eagle Pharmaceuticals EGRX
Quartalsbericht 2023-Q2
hinzugefügt 13.06.2026
Eagle Pharmaceuticals Langfristiger Schuldenstrom 2011-2026 | EGRX
Langfristiger Schuldenstrom Jährlich Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.53 M | 1.31 M | 1.12 M | 5 M | 6.25 M | 4.88 M | - | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 6.25 M | 1.12 M | 3.35 M |
Langfristiger Schuldenstrom anderer Aktien in der Arzneimittelhersteller
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
59.5 K | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
468 K | $ 5.6 | -1.23 % | $ 83.2 M | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
12.5 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
100 K | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
1.08 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
337 K | $ 2.68 | -2.55 % | $ 1.03 B | ||
|
Athenex
ATNX
|
2.09 M | - | -23.39 % | $ 1.76 M | ||
|
Harrow Health
HROW
|
887 K | $ 37.64 | -0.03 % | $ 1.38 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 1.0 | -0.99 % | $ 108 M | ||
|
Organogenesis Holdings
ORGO
|
4.95 M | $ 2.34 | -1.68 % | $ 297 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 22.99 | -1.58 % | $ 1.06 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 1.09 | -0.91 % | $ 1.35 M | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 3.04 | -1.3 % | $ 167 M | ||
|
Solid Biosciences
SLDB
|
2.1 M | $ 7.14 | -1.11 % | $ 625 M | ||
|
Jupiter Wellness
JUPW
|
23.5 K | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.06 | -1.85 % | $ 101 M | ||
|
Tilray
TLRY
|
2.47 M | $ 4.98 | -2.73 % | $ 3.08 B | ||
|
cbdMD
YCBD
|
778 K | $ 0.69 | -1.72 % | $ 2.78 M | ||
|
Evolus
EOLS
|
2.53 M | $ 6.73 | 3.38 % | $ 434 M | ||
|
Sundial Growers
SNDL
|
35.5 M | $ 1.42 | -2.74 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
2.4 M | $ 8.32 | -0.83 % | $ 445 M | ||
|
Veru
VERU
|
759 K | $ 3.0 | -7.98 % | $ 43.9 M | ||
|
Neoleukin Therapeutics
NLTX
|
3.05 M | - | - | $ 193 M | ||
|
Assertio Holdings
ASRT
|
240 K | $ 23.48 | 0.04 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
1.21 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
61 M | $ 5.06 | -1.94 % | $ 1.88 B | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
1.25 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
483 K | $ 4.23 | -0.35 % | $ 211 M | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
109 M | $ 16.48 | 1.04 % | $ 19.2 B | ||
|
Zomedica Corp.
ZOM
|
717 K | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
1.16 M | $ 0.62 | 0.35 % | $ 22.3 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
71.6 K | $ 0.71 | -6.82 % | $ 3.05 M | ||
|
TherapeuticsMD
TXMD
|
975 K | $ 2.2 | 20.88 % | $ 25.5 M |